Action Akero Therapeutics - AKRO

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

50,58

Prix Achat

49,60

Prix Vente

51,56

Volume échangé

810 688

50,12 Fourchette du Jour 51,3933

17,86 Plage de 52 semaines 58,40

Cap du marché

3,53B

Clôture Veille

50,67

Ouverture

50,82

Dernière Transaction

51.4

Dernière heure de transaction

23:21:25

Volume financier

US$ 41 112 816

VWAP

50,7135

Volume moyen (3 m)

1 267 688

Actions en circulation

69 799 148

Rendement du Dividende

Ratio Cours sur Bénéfices

-23,27

Bénéfice par action (BPA)

-2,17

Chiffre d'affairess

Bénéfice net

-151,76M

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company... Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis. Show more

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.akerotx.com

Siège social

Wilmington, Delaware, USA

Fondé

Akero Therapeutics Inc est coté dans le secteur Pharmaceutical Preparations de la NASDAQ avec le ticker AKRO. Le dernier cours de clôture d'Akero Therapeutics était de US$50,67. Au cours de la dernière année, les actions de Akero Therapeutics ont été négociées dans une fourchette de prix de US$ 17,86 à US$ 58,40.

Akero Therapeutics compte actuellement 69 799 148 actions en circulation. La capitalisation boursière d'Akero Therapeutics est de US$3,54 milliard. Akero Therapeutics a un ratio cours/bénéfice (ratio PE) de -23.27.

Form 4 - Statement of changes in beneficial ownership of securities

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a...

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	1.1	2.22312045271	49.48	51.3965	48.57	779527	49.92551477	CS
4	24.47	93.7188816545	26.11	58.4	25.69	2303125	51.53778246	CS
12	18.23	56.3523956723	32.35	58.4	21.34	1267688	42.27586936	CS
26	24.62	94.8382126348	25.96	58.4	21.34	857205	37.52246181	CS
52	29.84	143.87656702	20.74	58.4	17.86	922727	30.87081718	CS
156	32.8	184.476940382	17.78	58.4	7.52	905386	30.32080829	CS
260	27.23	116.616702355	23.35	58.4	7.52	632331	29.81796808	CS

AKRO - Frequently Asked Questions (FAQ)

What is the current Akero Therapeutics share price?

The current share price of Akero Therapeutics is US$ 50,58

How many Akero Therapeutics shares are in issue?

Akero Therapeutics has 69 799 148 shares in issue

What is the market cap of Akero Therapeutics?

The market capitalisation of Akero Therapeutics is USD 3,54B

What is the 1 year trading range for Akero Therapeutics share price?

Akero Therapeutics has traded in the range of US$ 17,86 to US$ 58,40 during the past year

What is the PE ratio of Akero Therapeutics?

The price to earnings ratio of Akero Therapeutics is -23,27

What is the reporting currency for Akero Therapeutics?

Akero Therapeutics reports financial results in USD

What is the latest annual profit for Akero Therapeutics?

The latest annual profit of Akero Therapeutics is USD -151,76M

What is the registered address of Akero Therapeutics?

The registered address for Akero Therapeutics is 1209 ORANGE STREET, NEW CASTLE, WILMINGTON, DELAWARE, 19801

What is the Akero Therapeutics website address?

The website address for Akero Therapeutics is www.akerotx.com

Which industry sector does Akero Therapeutics operate in?

Akero Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
MLGOMicroAlgo Inc	US$ 1,94 (68,70%)	9,76M
CELHCelsius Holdings Inc	US$ 32,75 (28,28%)	10,74M
UPCUniverse Pharmaceuticals Inc	US$ 0,182 (27,72%)	19,33M
GDYNGrid Dynamics Holdings Inc	US$ 24,15 (17,92%)	48,43k
INODInnodata Inc	US$ 62,11 (13,84%)	1,02M
CNTMConnectM Technology Solutions Inc	US$ 0,765 (-17,74%)	427,17k
AXTIAXT Inc	US$ 1,91 (-16,59%)	276,54k
APTOAptose Biosciences Inc	US$ 0,16 (-15,79%)	1,43M
MCVTMill City Ventures III Ltd	US$ 2,00 (-13,04%)	107,49k
JAKKJAKKS Pacific Inc	US$ 31,10 (-10,68%)	31,82k
UPCUniverse Pharmaceuticals Inc	US$ 0,182 (27,72%)	19,33M
RIVNRivian Automotive Inc	US$ 14,09 (3,53%)	10,9M
CELHCelsius Holdings Inc	US$ 32,75 (28,28%)	10,74M
MLGOMicroAlgo Inc	US$ 1,94 (68,70%)	9,76M
MNDRMobile health Network Solutions	US$ 0,8647 (-8,00%)	8,47M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Akero Therapeutics Inc (AKRO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Akero Therapeutics Inc

AKRO Dernières nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Form 8-K - Current report

AKRO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Akero Therapeutics Inc (AKRO) Cours

Akero Therapeutics Inc (AKRO)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Akero Therapeutics Inc

AKRO Dernières nouvelles

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Form 8-K - Current report

AKRO - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités